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Aim: To evaluate the effectiveness of intravenous magnesium sulphate in the treatment of acute asthmatic
attacks in children by meta-analysis.
Methods: A systematic and comprehensive search of the literature was performed to identify controlled
clinical trials of magnesium sulphate in paediatric acute asthma which evaluated outcomes of
hospitalisation or short term pulmonary function tests or symptom scores. Unpublished data were
searched by personal contacts with authors and specialists. Two reviewers independently assessed trial
qualities and synthesised data. Heterogeneity among studies was evaluated by the Cochrane Q test.
Outcome data were pooled by random or fixed effect models depending on presence or absence of
heterogeneity.
Results: Five randomised placebo controlled trials involving a total of 182 patients were identified. They
compared intravenous magnesium sulphate to placebo in treating paediatric patients with moderate to
severe asthmatic attacks in the emergency department, with co-therapies of inhaled b2 agonists and
systemic steroids. The studies were of high quality with results judged to be valid. Four studies showed that
magnesium sulphate was effective, while one study found it ineffective. There was no significant
heterogeneity in the primary outcome of hospitalisation. In the fixed effect model, magnesium sulphate is
effective in preventing hospitalisation (OR 0.290, 95% CI 0.143 to 0.589). The number needed to treat is 4
(95% CI 3 to 8). Secondary outcomes of short term pulmonary function tests and clinical symptom scores
also showed significant improvement.
Conclusion: Intravenous magnesium sulphate probably provides additional benefit in moderate to severe
acute asthma in children treated with bronchodilators and steroids.
B
ronchodilators (b2 agonists) and steroids are well
established effective treatments for all severities of
asthma.1–5 However, there are still children with mod-
erate to severe acute asthmatic attacks that may have
insufficient improvement, leading to hospitalisation or
intensive care unit (ICU) admission, and in the worst cases,
severe morbidity and even mortality. Anticholinergics and
methylxanthines have controversial efficacies.6–8 There is an
ongoing need to study new effective bronchodilating agents
as additional therapies for relieving moderate to severe
asthmatic attacks.
Magnesium sulphate is one of the agents being intensively
studied. Although a systematic review published by the
Cochrane Collaboration showed that magnesium sulphate is
effective in the treatment of severe acute asthma, it included
mainly adult studies.9 Whether intravenous magnesium
sulphate is effective in treating acute asthma in children is
still controversial.
We performed a meta-analysis to evaluate the effectiveness
of intravenous magnesium sulphate in preventing hospitali-
sation or ICU admission in children with acute asthmatic
attacks, either used alone or in addition to standard therapies.
METHODS
The search of relevant studies, assessment of trial qualities,
extraction of data, synthesis of data by meta-analysis,
examination of heterogeneity, and drawing of conclusions
were performed by two independent reviewers; discrepancies
were resolved by consensus.
Selection criteria
Inclusion criteria were controlled clinical trials of intravenous
magnesium sulphate of any therapeutic dose in children
below 18 years of age using outcome measures of hospitalisa-
tion, ICU admission, clinical symptom scores, or pulmonary
function tests. Both published and unpublished studies were
included. There was no language restriction. The exclusion
criterion was multiple publications.
Search strategies
Six databases (Medline, Pubmed, Embase, Cochrane Library,
Cochrane Central Register of Controlled Trials, and China
Journet Net) were searched under the following terms in the
keyword search: ‘‘magnesium’’ and ‘‘asthma’’ and ‘‘chil-
dren’’. Reference lists and citations of identified studies were
located by hand search to explore any published studies
missed. Personal contacts with authors and specialists were
made as far as possible to obtain unpublished data.
Quality assessment
The trial quality was assessed using the standard Jadad
score10 based on the adequacy of randomisation, blinding,
and follow up, with the maximum score of 5 points.
Data extraction
Baseline characteristics of treatment and control groups
including age, gender, baseline SpO2, symptom severity,
symptom scores, and results of pulmonary function tests
(PEFR, FEV1, and FVC) were extracted. The primary outcome
measure chosen was rate of hospitalisation or ICU admission,
expressed as odds ratio (OR) in treatment compared to
control group. Secondary outcome measures were rate of
persistent severe bronchoconstriction as indicated by PEFR
,60% predicted, between group difference in symptom
scores and percentage change of pulmonary function tests
at the end of the trial. Stratification of outcomes by treatment
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dose, age, and severity class (mild, moderate or severe) for
subgroup analyses would be performed if data were available.
Data analyses
Comprehensive meta-analysis software (available at http://
www.meta-analysis.com) was used for all statistical analyses.
Statistical heterogeneity in the outcome measures was
assessed using the Cochrane Q test, with p , 0.1 considered
as significant. The random effect model was used for pooling
results if significant statistical heterogeneity was present.
Otherwise the fixed effect model was used. Clinical hetero-
geneity among studies was explored in terms of study design,
patients recruited, baseline characteristics, intervention, co-
therapies, and outcome measures. Sensitivity analysis was
performed by reanalysis, excluding studies with poor quality
(Jadad score ,3).
RESULTS
Under the specified keyword search strategy, 35, 70, 31, 7, 9,
and 0 articles were identified in Medline, Pubmed, Embase,
Cochrane Library, Cochrane Central Register of Controlled
Trials, and China Journet Net respectively. Five independent
randomised placebo controlled trials satisfying inclusion
criteria were identified.11–15 No additional published or
unpublished article satisfying inclusion criteria was found
on hand search of the citations of these studies and personal
contacts.
All trials were carried out at emergency departments
comparing intravenous magnesium sulphate to placebo in
treating paediatric patients with acute moderate to severe
asthmatic attacks, with co-therapies of inhaled b2 agonists
and systemic steroids. All patients who entered the trials had
similar severity of asthma as indicated by inadequate
response to first line treatment with three doses of b2
agonists. All the studies were assessed to be of good quality
(Jadad score >4).
Table 1 presents the main results of individual studies and
the Jadad scores. Since no study mentioned rate of ICU
admission, we could only evaluate primary outcome of
hospitalisation. Table 2 shows the pooled effect size estimates
of primary and secondary outcomes and tests of hetero-
geneity. The pooled OR estimate for the primary outcome is
illustrated by the Forrest plot in fig 1.
Four of the studies concluded that magnesium sulphate
was effective in paediatric acute asthma while one study
found it to be ineffective. After pooling the results together,
intravenous magnesium sulphate was effective in avoiding
hospitalisation. The absolute risk reduction (ARR) for
hospitalisation is 0.257 (95% CI 0.124 to 0.389, p=0.0001).
The number needed to treat (NNT) in avoiding hospitalisa-
tion is 4 (95% CI 3 to 8).
The pooled result on short term lung function suggested
that there was an approximately 85% reduction in risk of
persistent bronchoconstriction with PEFR ,60% of predicted
values, with all studies showing consistent reduction in risks,
although to somewhat different extent.
The pooled result on asthma symptom score also showed
significant improvement, with individual studies showing
consistent results. It was noted that two different scoring
systems were used in the studies, with three of the studies12–15
using the clinical asthma symptom score and one using the
pulmonary index. However, their results pointed in the same
direction, favouring treatment compared to placebo with
statistical significance, irrespective of the scoring system
used.
No subgroup analysis was performed in different age
groups because stratified outcome data were not available in
any of the studies. Since all studies included only patients
with moderate to severe asthma, we could not evaluate the
efficacy of magnesium sulphate in mild asthma. No study
compared the effectiveness of different dosages of magne-
sium sulphate, and therefore we could not further evaluate
the dose-response relation. Sensitivity analysis was not
performed because of the small number of studies and
similarity of trial quality. Possible areas of heterogeneity of
the trials are shown in table 3 (available on the ADC website).
Table 1 Main results of individual studies
Outcome measures Ciarallo L, 1996 Devi PR, 1997 Gurkan F, 1999 Cariallo L, 2000 Scarfone RJ, 2000
OR of hospitalisation (95% CI) 0.077
(0.004 to 1.582)
0.235
(0.066 to 0.841)
N/A 0.035
(0.002 to 0.676)
0.740
(0.252 to 2.173)
OR of persistent PEFR ,60%
predicted (95% CI)
0.165
(0.035 to 0.785)
0.125
(0.021 to 0.753)
0.184
(0.027 to 1.244)
N/A N/A
Percentage change of PEFR
at study end: treatment v
placebo; mean (SD)
59% (20%) v 20%
(11%) (p = 0.05)
N/A 58.4% (2.9%) v
21.8% (4.5%)
(p = 0.0001)
87% (7%) v 7% (2%)
(p,0.001)
N/A
Clinical symptom score at
study end: treatment v placebo;
mean (SD)
N/A 6 v 7 (CAS)
(p,0.01)
2.5 (0.5) v
4.3 (0.3) (CAS)
(p,0.001)
1.1 v 2.4 (CAS)
(p,0.001)
5.3 (2.8) v 6 (2.9)
(PI) (p = 0.001)
Jadad score 4 4 4 4 5
N/A, data not available; CAS, clinical asthma symptom score; PI, pulmonary index.
Table 2 Pooled effect size estimates and tests of heterogeneity
Outcome measures Model
Studies included
(reference no.)
Pooled point
estimate 95% CI p value
Q test of heterogeneity
p value (df)
OR of hospitalisation Mantel-Haenszel fixed
effect model
11, 12, 14, 15 0.290 0.143 to 0.589 0.0006 0.13 (df = 3)
OR of persistent PEFR ,60%
predicted
Mantel-Haenszel fixed
effect model
11, 12, 13 0.155 0.057 to 0.422 0.0003 0.97 (df = 2)
Difference in percentage
improvement of PEFR at
study end
Hedges’s random effect
model
11, 13, 14 8.58 0.94 to 16.22 0.028 ,0.0001 (df = 2)
Difference in clinical symptom
score at study end
Hedges’s random effect
model
12, 13, 14, 15 1.33 0.31 to 2.36 0.011 0.0001 (df = 3)
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DISCUSSION
This is the first meta-analysis investigating the effectiveness
of intravenous magnesium sulphate in treating acute child-
hood asthma; it showed a favourable effect. The NNT in
avoiding hospitalisation is only four, implying probable high
cost effectiveness. In addition to b2 agonists and systemic
steroids, intravenous magnesium sulphate also appears
effective in relieving bronchoconstriction and improving
asthma symptoms.
Three different single dose regimes of intravenous magne-
sium were used in the five studies: 25 mg/kg in two studies,
40 mg/kg in two, and 75 mg/kg in one. Interestingly, one
study using 25 mg/kg and another study using 40 mg/kg
magnesium showed a significant reduction in the rate of
hospitalisation, whereas the other study using 25 mg/kg and
the study using 75 mg/kg magnesium reported an insignif-
icant effect on hospitalisation. Whether this inconsistency in
dose-response relation is related to intrinsic dosage related
effect or confounding factors such as criteria of hospitalisa-
tion is not apparent in the current meta-analysis and requires
further evaluation in future studies. However, the incon-
sistent dosage effect might reflect a small sample size of
individual studies, resulting in inadequate statistical power to
detect a significant effect, especially in view of the consistent
trend of reduction in hospitalisation and statistical homo-
geneity of this primary outcome across studies. Nevertheless,
we observed no clear evidence to suggest that higher dosage
of magnesium results in better outcomes; further studies are
therefore needed to identify the optimal dosage of magne-
sium with maximal efficacy.
Intravenous magnesium sulphate therapy was well toler-
ated with only minor side effects reported, such as epigastric
or facial warmth, flushing, pain and numbness at infusion
site, dry mouth, and malaise.12 16 It is generally safe to be used
in children with moderate to severe acute asthma, although
rare adverse effects might have escaped detection in the small
samples.
The mechanism of action of magnesium sulphate is not
clearly defined. Magnesium ion decreases the uptake of
calcium by bronchial smooth muscle cells, which in turn
leads to bronchodilation.17 Magnesium may also have a role
in inhibiting mast cell degranulation, thus reducing inflam-
matory mediators such as histamine, thromboxanes, and
leukotrienes.17 In addition, magnesium inhibits the release of
acetylcholine from motor nerve terminals and depresses the
excitability of muscle fibre membranes.18 19
There were several limitations in the current meta-analysis.
Firstly, studies were heterogeneous with respect to patient
inclusion criteria, baseline characteristics, magnesium sul-
phate dosage, co-therapies, and outcome measures, although
there was no statistically significant heterogeneity in the
primary outcome. Hence care should be taken in applying the
pooled result to individual patients in clinical practice.
Secondly, the total number of patients involved in all the
studies combined is still relatively small. The study by
Scarfone and colleagues15 comprised about 30% of patients
and concluded that magnesium is ineffective. Two of the five
studies reporting effectiveness of magnesium had the same
first author11 14 and involved one third of the total number of
patients. Thirdly, the pooled effect estimate, though sig-
nificant statistically, was not precise as only a few studies
have been performed. Fourthly, subgroup analysis was not
possible because stratification of outcomes or raw data were
not available. Finally, publication bias might be present as
suggested by funnel plot asymmetry (fig 2). Unpublished
negative studies might have been missed.
Conclusion
Based on existing data, intravenous magnesium sulphate is
likely to be effective in avoiding hospitalisation and improv-
ing bronchoconstriction and clinical symptoms of moderate
to severe acute asthma in children, when added to standard
therapies of inhaled bronchodilators and systemic steroids.
Further studies are needed to evaluate the effectiveness of
intravenous magnesium sulphate in different severity classes
of asthma and in patients of different age groups. Studies
should also aim at further defining the indications, possible
contraindications, and optimal dosage of intravenous mag-
nesium sulphate.
Table 3 is available on the ADC website (www.
archdischild.com/supplemental)
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Figure 1 Forrest plot of odds ratio of hospitalisation.
Figure 2 Funnel plot of precision by effect size.
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Running for the line
I
n 1823, while playing a game of soccer at school, William Webb-Ellis broke the rules. He
picked up the ball and ran the whole length of the pitch with it. This memorial statue is in the
town of Rugby, which gave its name to the game that his impulsive act inspired.
Most paediatricians get referrals about children with behaviour problems. Some referrals are
justified, but in our experience they often stem from the hope that some ‘‘physical’’ cause will
be found, one which is treatable if not curable by a tablet.
Do these children need to see a doctor? There is rarely a physical cause. Of course we need to
consider conditions such as ADHD, but these are a minority.
A child’s behaviour can be uncomfortable for adults. If we were children now, how many of
us would end up being referred for the same ‘‘behaviour difficulties’’ we as doctors are asked to
consult on. As Webb-Ellis showed, the ability to think and act ‘‘outside the box’’ may have
remarkable results. It is a shame if children cannot be allowed to do anything different without
someone deciding this is a ‘‘medical problem’’. We should encourage creativity within our
children and resist the medicalisation of childhood.
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